CMC(SH:603122) Zheng Quan Ri Bao·2025-11-12 04:37Core Viewpoint - Despite ongoing losses, HeFu China (603122.SH) has experienced a dramatic stock price surge, achieving a "12 days 11 boards" performance, with a cumulative increase of 200.75% from October 28 to November 12, raising its market capitalization from under 3 billion to 8 billion [2][4]. Company Performance - HeFu China's stock price rose from 6.65 yuan per share on October 28 to 20.09 yuan on November 12, marking a total increase of 200.75% [2][4]. - The company reported a revenue of 549 million yuan for the first three quarters of 2025, a year-on-year decline of 22.80%, and a net profit attributable to shareholders of -12.39 million yuan, down 146.65% year-on-year [5][6][7]. Business Operations - HeFu China's business scope includes AI-assisted clinical diagnosis systems, remote medical services, hospital management, cross-strait medical cooperation, and precision management of in vitro diagnostic reagents [4]. - The company has been subject to significant stock price speculation, with frequent trading risk warnings issued, indicating a severe deviation from its fundamental performance [4][5]. Market Sentiment and Speculation - The stock has been heavily traded, with 11 instances of being on the trading leaderboard in the past month, accumulating a net buy of 119 million yuan [7]. - Analysts suggest that the stock's rapid rise is driven by speculative trading rather than fundamental support, indicating a potential for sharp declines once speculative interest wanes [8].